URGN

UroGen Pharma Ltd

URGN, USA

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

https://www.urogen.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
URGN
stock
URGN

The growth track for UroGen Pharma Ltd (URGN) has changed recently Setenews

Read more →
URGN
stock
URGN

UroGen Pharma (URGN) Issues Stock Units to New Employees GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$35.25

Analyst Picks

Strong Buy

5

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-9.08

Low 1

High 3

Return on Equity (ROE)

-

Very High

28.89 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-18.02 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-154.13 %

Low 5%

High 15%

Investors

* Institutions hold a combined 79.20% of the total shares of UroGen Pharma Ltd

1.

BioPharma Credit Ord

(10.1479%)

since

2024/12/31

2.

RTW INVESTMENTS, LLC

(9.8216%)

since

2025/06/30

3.

The Toronto-Dominion Bank

(6.8963%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(5.3572%)

since

2025/06/30

5.

BlackRock Inc

(5.1989%)

since

2025/06/30

6.

Jefferies Financial Group Inc

(4.7546%)

since

2025/06/30

7.

Soleus Capital Management, L.P.

(4.7229%)

since

2025/06/30

8.

SILVERARC CAPITAL MANAGEMENT, LLC

(4.3716%)

since

2025/06/30

9.

MENORA MIVTACHIM HOLDINGS LIMITED

(2.4912%)

since

2025/06/30

10.

SG Americas Securities, LLC

(2.4837%)

since

2025/06/30

11.

TANG CAPITAL MANAGEMENT LLC

(2.1615%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(1.9192%)

since

2025/08/31

13.

Adage Capital Partners Gp LLC

(1.794%)

since

2025/06/30

14.

State Street Corp

(1.7457%)

since

2025/06/30

15.

Migdal Insurance & Financial Holdings Ltd

(1.6663%)

since

2025/06/30

16.

Kynam Capital Management, LP

(1.4192%)

since

2025/06/30

17.

Millennium Management LLC

(1.284%)

since

2025/06/30

18.

Boxer Capital Management, LLC

(1.2429%)

since

2025/06/30

19.

Citadel Advisors Llc

(1.1741%)

since

2025/06/30

20.

Rosalind Advisors, Inc.

(1.1723%)

since

2025/06/30

21.

Wildcat Capital Management, LLC

(1.0713%)

since

2025/06/30

22.

Susquehanna International Group, LLP

(1.0479%)

since

2025/06/30

23.

Fidelity Small Cap Index

(0.7994%)

since

2025/06/30

24.

iShares Russell 2000 Growth ETF

(0.572%)

since

2025/08/31

25.

iShares Biotechnology ETF

(0.5044%)

since

2025/08/31

26.

Nuveen Quant Small Cap Equity R6

(0.4243%)

since

2025/07/31

27.

Vanguard Russell 2000 ETF

(0.3802%)

since

2025/07/31

28.

SPDR® Portfolio Developed Wld ex-US ETF

(0.3527%)

since

2025/08/29

29.

State St Russell Sm Cap® Indx SL Cl I

(0.2907%)

since

2025/08/31

30.

ARK Israel Innovative Technology ETF

(0.2789%)

since

2025/08/28

31.

Schwab Small Cap Index

(0.2008%)

since

2025/07/31

32.

NT R2000 Index Fund - NL

(0.193%)

since

2025/06/30

33.

iShares Micro-Cap ETF

(0.18%)

since

2025/08/31

34.

Vifag 2002 SICAV

(0.1708%)

since

2025/07/31

35.

Allianz Biotechnologie P EUR

(0.1659%)

since

2025/07/31

36.

iShares Russell 2000 Value ETF

(0.1596%)

since

2025/08/31

37.

NT R2000 Index Fund - DC - NL - 3

(0.1539%)

since

2025/06/30

38.

Oak Ridge Sm to Md-Cap Eq Comp

(0.1525%)

since

2025/06/30

39.

SPDR® Russell 2000 US Small Cap ETF

(0.1378%)

since

2025/08/31

40.

iShares Russell 2000 Small-Cap Idx Instl

(0.1347%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.69

EPS Estimate

-0.6434

EPS Difference

-0.0466

Surprise Percent

-7.2428%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(3.5)
Growth
Moderate Growth(3.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.